IFF expands LMR Naturals site in Grasse, advancing naturals innovation leadership
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, today inaugurated its expanded LMR Naturals site in Grasse following a €10 million investment. The expansion increases the facility’s footprint by 75 percent to 4,687 square meters and includes a state-of-the-art pilot hall designed to accelerate the development of new natural ingredients. The upgraded site also counts on a newly completed experimental field nearby that will provide direct access to plant materials, enabling deeper exploration of botanical potential and fast-tracking ingredient innovation. The expansion brings together more than 30 research and development experts under one roof, enhancing IFF’s ability to meet rising global demand for traceable, sustainable and high-quality naturals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908487443/en/
Credit: IFF
“LMR Naturals is a strategic asset in IFF’s portfolio, and this expansion underscores our commitment to shaping the future of natural ingredients,” said Erik Fyrwald, IFF CEO. “By deepening our roots in Grasse — the global center of excellence for natural ingredients — we’re scaling innovation that empowers perfumers and flavorists worldwide to deliver high-performing, exceptional and sustainable signatures consumers trust.”
LMR Naturals is a trademarked capability within IFF, originally founded in 1983 by Monique Remy and acquired by IFF in 2000 to enhance IFF’s ability to provide perfumers with high-quality, innovative and, sustainably sourced and produced natural ingredients at competitive cost. Today, perfumers around the world leverage the deep expertise of LMR scientists to create the signature of unforgettable fragrances for customers and across applications such as fine perfumery, cosmetics, home care, fabric care and beauty care. LMR Naturals also provides ingredients for taste applications.
“LMR’s ability to fuse tradition with cutting-edge innovation is unmatched,” said Sabrya Meflah, president of IFF’s fine fragrance segment. “This expansion is more than bricks and mortar—it’s a launchpad for the next generation of naturals that will shape the future of fine perfumery, with applications across all IFF businesses. Our footprint in Grasse now enables a seamless transition from seed to bottle, with our Atelier du Parfumeur just steps away.”
“With a newly expanded site now fully operational, we intend to launch four to six new products each year, with sustainability at the heart of our approach — reflected in our dual certifications, For Life and Zero Waste to Landfill, and a waste valorization rate of at least 98 percent,” said Bertrand de Preville, general manager of LMR Naturals.
LMR Naturals introduced 23 new ingredients since 2020 and earned notable accolades, including seven awards from CosmetiqueMag and recognition from the Organic Monitor Sustainable Beauty Awards. Meanwhile, the LMR Naturals team remains committed to its founding vision: revealing the purity of natural ingredients while respecting the environment and sourcing partners. LMR currently processes 85,000 tons of biomass annually, produces 2,000 tons of extracts and offers more than 850 ingredients across 130 botanical families.
With this expansion, IFF reaffirms its strategic investment in the Grasse region, which now includes more than 230 employees and positions it as a global hub for natural ingredient innovation and excellence.
Visit LMR Naturals at https://lmrnaturals.iff.com, LinkedIn, and Instagram.
Cautionary Statement under the Private Securities Litigation Reform Act of 1995
This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “plan”, “expect,” “anticipate,” “intend,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the expansion, its operations or future product launches. There are many risks and uncertainties inherent in our business that could cause actual results and events to differ materially from those in the forward-looking statements. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances.
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.
© 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908487443/en/
Contacts
Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owlet Makes Premium Monitoring Possible for Every Family With New Dream Sight™ Video Monitor9.9.2025 14:45:00 EEST | Press release
Owlet, Inc. (NYSE: OWLT) (the “Company” or “Owlet”), the pioneer of smart infant monitoring, announces the launch of its new HD video baby monitor, Dream Sight™, and next-generation Dream Duo™. These products represent an important step for Owlet in the category, featuring advanced technology designed to provide clarity, connection, and peace of mind from day one. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909618049/en/ Owlet's Dream Sight 2K HD Video Monitor. “Parents are clear about what they need in a baby monitor – more advanced features, greater reliability, deeper security, and a price point that makes sense,” said Kurt Workman, Owlet’s Chief Executive Officer and Co-Founder. “Dream Sight is a direct response to that feedback from our customers. When paired with our medically-certified Dream Sock®, it creates a connected monitoring experience that gives caregivers the confidence and peace of mind they need.” Int
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer9.9.2025 14:43:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable (MSS) metastatic colorectal cancer (mCRC) under France’s compassionate access (Accès compassionnel, or AAC) framework. The French National Agency of Medicines and Health Products Safety’s (ANSM) listings for botensilimab and balstilimab are live and detail eligibility (including MSS and no active liver metastases) and dosing. BOT/BAL remains investigational and is not approved for commercial marketing in France or elsewhere. How AAC reimbursement works Once the ANSM authorizes AAC, hospital use is covered 100% by Assurance Maladie. Hospitals are reimbursed at the invoiced purchase price (TTC), outside the Diagnosis-related Group (DRG), referred to in France as “en sus du GHS”. During AAC the manufacturer either provides the medicine free of charge or invoices an “indem
Promega and Watchmaker Genomics Announce Strategic Partnership to Advance Molecular Analysis with Next-Generation Reverse Transcriptase9.9.2025 14:11:00 EEST | Press release
Promega Corporation has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase. Designed for enhanced accuracy and sensitivity in RNA analysis, the enzyme will enhance Promega capabilities to manufacture and deliver both catalog and customized solutions for clinical, applied and pharmaceutical molecular applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908209296/en/ “Watchmaker’s enzyme offers a combination of attributes that establish a new benchmark for reverse transcriptase performance,” says Sara Mann, VP of Commercial Excellence at Promega. “By incorporating it into our portfolio, we are giving customers a powerful tool for improved accuracy and enhanced sensitivity of RNA-based assays.” This partnership marks the beginning of an expanded collaboration between Watchmaker Genomics and Promega, with both companies committed to developing next-generation e
Kinaxis Powers Shimadzu’s Supply Chain Advancement for the Modern Manufacturing Era9.9.2025 14:00:00 EEST | Press release
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that Shimadzu Corporation, a top manufacturer of high-technology precision instruments, has selected the Kinaxis Maestro® platform to advance its supply chain strategy and outmaneuver global trade volatility. Shimadzu is turning to Maestro to simulate real-world trade scenarios, align cross-functional teams and proactively act before disruption hits. Shimadzu makes precision equipment for high-stakes industries from pharmaceuticals to aerospace where speed and foresight are critical. As they expand globally, Shimadzu needed a supply chain technology platform that could process complex data, provide instant optionality and protect profits as it navigates a dynamic global tariff and trade environment. “We have built our reputation on precision, innovation and excellence for our partners,” said Akira Okubo, corporate officer, general manager, DX・IT strategy management department at Shimadzu Corpo
IFF launches interactive platform to inspire adult beverage innovation9.9.2025 14:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in food, beverage, health and wellness, has unveiled SipScape, a new platform designed to inspire innovation across the rapidly evolving adult beverage landscape. It offers actionable insights and trends, including product design, flavor modulation and sweetness reduction in no-and low-alcohol beverages. The platform also highlights IFF’s expertise in incorporating botanicals, natural colors and other functional additions based on current trends and market demands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909611189/en/ Photo credit: IFF “Understanding how and why people drink today is essential to staying ahead,” said Fernanda De Paula, vice president of global beverages category for IFF Taste. “Consumers are looking for more than a buzz, and drinks are no longer defined solely by their alcohol content. The most successful new products are those that reflect people’s values, fulfill
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom